Sickle Blow For Pfizer’s Rivipansel At Phase III RESETs Expectations

After a long wait, the top-line data for Pfizer’s RESET study of the investigational treatment for sickle cell disease disappoint. Shares in rivipansel’s originator GlycoMimetics halved on the news.